Background and aims While inhibition of proprotein convertase subtilisin/kexin type 9
(PCSK9) is known to result in dramatic lowering of LDL-cholesterol (LDL-C), it is poorly
understood how it affects other lipid species and their metabolism. The aim of this study was
to characterize the alterations in the lipidome of plasma and lipoprotein particles after
administration of PCSK9 inhibiting antibody to patients with established coronary heart
disease. Methods Plasma samples were obtained from patients undergoing a randomized …